NAFLD Clinical Care Pathway
VA Office of Research and Development · NCT06671886
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 32
- US sites recruiting
- 1
- Study start
- February 2, 2024
- Record last updated
- November 14, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD. Therefore, the burden of NAFLD and its complications among Veterans is substantial. However, most VA patients with NAFLD are undiagnosed and untreated, and their care is not consistent with practice guidelines. The NAFLD Clinical Care Pathway (NCCP) intervention seeks to close this major gap in the care of Veterans by automatically identifying patients at risk of NAFLD, calculating their risk scores of having severe NAFLD, and educating the primary care providers on the diagnosis and treatment of NAFLD. This clinical trial will test the benefit of this NCCP intervention against usual care in increasing the rates of NAFLD diagnosis as well as referral to and enrollment in appropriate treatment. The study will also identify barriers and promotors of future NCCP implementation.
Being studied: E-trigger
Conditions: NAFLD; MASLD
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Patient Aligned Care Teams (PACT) at the Michael E. DeBakey VA Medical Center
Exclusion Criteria
- The investigators will exclude PACTs with unstable leadership (i.e., pending departure, vacancy) at time of randomization.
- PACTs participating in the focus groups in Aim 1 will be excluded in Aim 2 to avoid cross contamination.
- PACTs meeting the following criteria will be excluded from randomization in Aim 2:
- PACTs who do not treat NAFLD,
- PACTs not located at the main hospital,
- PACTs with less than 100 visits within 3 months.
Recruiting US locations
Michael E. DeBakey VA Medical Center, Houston, TX
Houston, TX 77030-4211
Site contact: Hashem B El-Serag, MD MPH · 713-794-8640 · Hashem.El-Serag@va.gov
Study contacts (from the official record)
- Hashem B El-Serag, MD MPH · (713) 794-8640 · Hashem.El-Serag@va.gov
- Kyler Godwin, PhD MPH BS · (713) 440-4672 · kyler.godwin@va.gov
Similar studies in Texas
All nutrition & metabolism studies in Texas →- RecruitingHealthy volunteersPhase 1/Phase 2
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Regeneron Pharmaceuticals
- Location
- Houston, TX + 4 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
Opus Genetics, Inc
- Location
- Houston, TX + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
Boehringer Ingelheim
- Location
- Arlington, TX + 18 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Pfizer
- Location
- Houston, TX + 29 other US sites
- Eligibility basics
- Ages 18+